H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric Gliomas

H3.3-G34R 突变介导的表观遗传重编程可增强弥漫性半球胶质瘤免疫刺激基因治疗的疗效

阅读：9
作者：Maria B Garcia-Fabiani, Santiago Haase, Kaushik Banerjee, Ziwen Zhu, Brandon L McClellan, Anzar A Mujeeb, Yingxiang Li, Claire E Tronrud, Maria L Varela, Molly E J West, Jin Yu, Padma Kadiyala, Ayman W Taher, Felipe J Núñez, Mahmoud S Alghamri, Andrea Comba, Flor M Mendez, Alejandro J Nicola Candia,
期刊：bioRxiv影响因子：
时间：2025起止号：2025 Feb 5:2023.06.13.544658.
doi：10.1101/2023.06.13.544658靶点： AROS
研究方向： 免疫、表观遗传疾病类型： 胶质瘤

Significance

This study uncovers the role of the H3.3-G34 mutation in reprogramming the tumor immune microenvironment in diffuse hemispheric gliomas. Our findings support the implementation of precision medicine informed immunotherapies, aiming at improving enhanced therapeutic outcomes in adolescents and young adults harboring H3.3-G34 mutant DHGs.

Statement of significance

This study uncovers the role of the H3.3-G34 mutation in reprogramming the tumor immune microenvironment in diffuse hemispheric gliomas. Our findings support the implementation of precision medicine informed immunotherapies, aiming at improving enhanced therapeutic outcomes in adolescents and young adults harboring H3.3-G34 mutant DHGs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。